回生口服液对急性放射性食管炎防治作用的临床疗效

Effects of Huisheng Koufuye in prevention and treatment of acute radiation-induced esophagitis

目的:观察回生口服液防治急性放射性食管炎的疗效.方法:将86例确诊为肺癌、食管癌、胸腺瘤且需行放射治疗的患者随机分为治疗组和对照组,每组各43例.治疗组自放疗开始前7 d起服用回生口服液,对照组则于出现放射性食管炎症状后给予自制复方普鲁卡因止痛合剂治疗,自入组患者出现放射性食管炎临床症状并应用药物起计治疗时间,7 d为1个周期,观察疗程为4个周期.参照美国放射治疗肿瘤组(The Radiation Therapy Oncology,RTOG)毒性标准分级,比较两组患者放射治疗完成率,急性放射性食管炎的发生率、出现时间、缓解程度以及放疗过程中的并发症及药物不良反应.结果:治疗组的放射治疗完成率为100%,对照组完成率为86.05%.治疗组急性放射性食管炎的发生时间为开始放疗后18.9 d±0.5 d,较对照组(13.1 d±0.7 d)明显推迟(P<0.05);发生率分别为79.07%和95.35%(P<0.05),而总有效率分别为93.02%和76.74%(P<0.05).并且,对照组出现4例因严重并发症而被迫中断治疗.结论:回生口服液可以有效推迟急性放射性食管炎的发生时间,明显降低发生率,延缓病情进展,提高患者顺应性,保障放疗顺利进行,提高近期疗效.

AIM： To evaluate the effects of Huisheng Kou- fuye in prevention and treatment of acute radia- tion-induced esophagitis. METHODS： Eighty-six patients diagnosed with lung cancer, esophageal cancer and thymoma scheduled for radiation therapy were randomly divided into either a treatment group or a con- trol group （n = 43 for each group）. The treatment group was given Huisheng Koufuye from seven days before radiotherapy, while the control group was given compound procaine pain killing mix- ture after the occurrence of radiation-induced esophagitis. The treatment time was recorded since the occurrence of clinical symptom （radia- tion esophagitis） in enrolled patients and the use of drugs. With seven days as a cycle, the observed course of treatment included four cycles. Referring to the toxicity grading criteria by United States Radiation Therapy Oncology Group （RTOG）, the completion rate of radiation therapy, the incidence rate of acute radiation-induced esophagitis, the onset time, the degree of ease, complications and toxic and adverse effects during radiotherapy were compared between the two groups. RESULTS： The completion rate of radiation therapy was 100% in the treatment group and 86.05% in the control group. The onset time of acute radiation-induced esophagitis was 18.9 d ＋ 0.5 d after radiotherapy in the treatment group and significantly delayed compared with the control group （13.1 d ±0.7 d, P 〈 0.05）. The incidence rate of acute radiation-induced esophagitis （79.07% vs 95.35%, P 〈 0.05） and the total effective rate （93.02% vs 76.74%, P 〈 0.05） differed significantly between the treatment group and control group. In addition, four cases discontin- ued treatment in the control group due to serious complications. CONCLUSION： Huisheng Koufuye can effectively postpone the occurrence of acute radia- tion-induced esophagitis, significantly reduce its incidence, delay the disease progression, improve patient＇s compliance, guarantee the smooth progress of radiotherapy, and improve the short-term effect in cancer patients receiving radiation therapy.